We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Galapagos Presents Favorable Phase 1 Data for IBD Target


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Presents Favorable Phase 1 Data for IBD Target "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

The oral presentation entitled, “GPR84, a novel target for the development of therapies in IBD,” (abstract OP183), will take place in the Free Paper Session “Towards better understanding of IBD pathogenesis,” at 12.00 PM in Hall N on 21 October, 2014. Galapagos will present compelling pre-clinical evidence for GPR84 playing a key role in IBD pathology. The discovery of a selective antagonist of GPR84 led to GLPG1205, which shows strong efficacy in relevant pre-clinical models for IBD. 

Galapagos will also present a poster on the safety and druglike properties of GLPG1205 in clinical Phase 1: “Human safety, pharmacokinetics and pharmacodynamics of the GPR84 antagonist GLPG1205, a potential new approach to treat IBD,” (P0341), today in Hall XL from 9.00 – 17.00. GLPG1205 was shown to be safe and generally well tolerated in healthy volunteers up to 100 mg daily. The drug shows a favorable PK/PD profile, clearly demonstrating the ability of the compound to engage GPR84. Once-daily dosing of GLPG1205 resulted in a sustained and extensive full 24-hour inhibition of GPR84 ligand binding. 

Both the slides and poster are available on www.glpg.com

In 2007, Galapagos announced an alliance agreement with Janssen Pharmaceutica NV providing the option to worldwide, commercial licenses to certain Galapagos internal inflammatory disease programs. These programs include novel targets for inflammatory disorders that were identified and validated by Galapagos using its proprietary target discovery engine. Subsequent Galapagos research led to the discovery of novel compounds acting on those targets. Galapagos is responsible for execution of Phase 1 and Phase 2A studies with compounds in the alliance. 

Advertisement